相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study
Gunter von Minckwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Retrospective Evaluation of Clinical Outcomes in Patients with HER2-Positive Advanced Breast Cancer Progressing on Trastuzumab-Based Therapy in the Pre-Lapatinib Era
Filippo Montemurro et al.
CLINICAL BREAST CANCER (2008)
Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer
Rupert Bartsch et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
Charles E. Geyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Phosphoproteomic analysis of Her2/neu signaling and inhibition
Ron Bose et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer
Rita Nahta et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2006)
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment:: The M77001 study group
M Marty et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression
D Tripathy et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel
B Leyland-Jones et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
分享论文
